Key result
Inhaled iloprost significantly reduced mean pulmonary artery pressure from 39.9 mmHg to 32.5 mmHg at a median follow-up of 8.5 months in patients with pulmonary arterial hypertension receiving combination therapy.
Why the study?
Inhaled iloprost is an established treatment for PAH, but the long-term hemodynamic changes it induces remain unclear.
Does inhaled iloprost improve long-term hemodynamic parameters in patients with pulmonary arterial hypertension receiving combination therapy?
Observational (n=18)
No
Does inhaled iloprost improve long-term hemodynamic parameters in patients with pulmonary arterial hypertension receiving combination therapy?
Inhaled iloprost added to oral combination therapy in PAH patients provides both acute vasodilation and significant long-term improvements in pulmonary hemodynamics.
Answers are grounded in this paper and cite their sources.
Supports inhaled iloprost consideration in PAH on combination therapy; leaves open confirmation via randomized trials.
Inhaled iloprost is an established treatment for pulmonary arterial hypertension (PAH). However, the long‐term hemodynamic changes that inhaled iloprost induces are unclear. Here, we retrospectively enrolled 18 patients with PAH who received inhaled iloprost as add‐on to oral combination therapy from December 2016 to January 2021 at our institute in Japan. We then examined the changes in hemodynamic parameters induced by iloprost in these patients during right heart catheterization (RHC). To examine the long‐term effects of iloprost, we repeated the RHC examination at follow‐up (median time to follow‐up, 8.5 months). During both catheterization procedures, iloprost was administered by using an I‐neb AAD system (Philips NV). In a comparison of pre‐inhalation values at the first and follow‐up RHCs, inhaled iloprost significantly improved mean pulmonary artery pressure (mPAP; 39.9 ± 7.8 to 32.5 ± 7.2 mmHg, p = 0.016) and pulmonary vascular resistance (PVR; 588.5 ± 191.7 to 464.4 ± 188.5 dyn s cm −5 , p = 0.047). During the follow‐up RHC, in a comparison of the pre‐inhalation and best recorded values out to 30 min after the end of iloprost inhalation, iloprost significantly decreased mPAP (32.5 ± 7.2 to 30.0 ± 6.6 mmHg, p = 0.007) and PVR (457.8 ± 181.4 to 386.2 ± 142.8 dyn s cm −5 , p = 0.025) and significantly increased cardiac output (4.19 ± 0.91 to 4.64 ± 1.01 L/min, p = 0.035). Iloprost may have not only acute vasodilation effects but also long‐term hemodynamic benefits in PAH patients receiving combination therapy.
No takes yet. Share an insight, caveat, or question.
Yasuda et al. (2022) conducted an observational in Pulmonary arterial hypertension (n=18). Inhaled iloprost vs. Baseline (pre-inhalation) was evaluated on Mean pulmonary artery pressure (mPAP) at follow-up (p=0.016). Inhaled iloprost significantly reduced mean pulmonary artery pressure from 39.9 mmHg to 32.5 mmHg at a median follow-up of 8.5 months in patients with pulmonary arterial hypertension receiving combination therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: